Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 21, 2021 - Issue 9
Submit an article Journal homepage
307
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy

Arianna Zangrillia Department of Dermatology, University of Rome Tor Vergata, Rome, ItalyORCID Iconhttps://orcid.org/0000-0003-4983-4420View further author information
ORCID Icon,
Giacomo Caldarolab Department of Dermatology, Università Cattolica Del Sacro Cuore, Rome, Italy;c Department of Dermatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ItalyORCID Iconhttps://orcid.org/0000-0002-8837-9232View further author information
ORCID Icon,
Nicoletta Bernardinid Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit “Daniele Innocenzi,” Sapienza University of Rome, Rome, ItalyView further author information
,
Mauro Bavettaa Department of Dermatology, University of Rome Tor Vergata, Rome, ItalyORCID Iconhttps://orcid.org/0000-0001-7552-5176View further author information
ORCID Icon,
Dario Graceffae Department of Dermatology, Istituto Dermatologico San Gallicano – IRCCS, Roma, ItalyView further author information
,
Claudio Bonifatie Department of Dermatology, Istituto Dermatologico San Gallicano – IRCCS, Roma, ItalyORCID Iconhttps://orcid.org/0000-0001-7752-4337View further author information
ORCID Icon,
Franca Cantoresif Unit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, ItalyView further author information
,
Sara Falerig Department of Dermatology, UOC DERMATOLOGIA dell’Ospedale Di Belcolle, Viterbo, ItalyView further author information
,
Domenico Giordanoh NESMOS Department, Dermatology Unit, Sant’Andrea Hospital, University of Rome Sapienza, ItalyORCID Iconhttps://orcid.org/0000-0003-0624-2097View further author information
ORCID Icon,
Marco Marianii Section of Hygiene, University Department of Health Sciences and Public Health, Università Cattolica Del Sacro Cuore, Rome, ItalyORCID Iconhttps://orcid.org/0000-0001-7799-4291View further author information
ORCID Icon,
Adriana Michelij Unità Di Dermatologia, Ospedale Nuovo Regina Magherita, Roma, ItalyView further author information
,
Gaia Morettak Department of Dermatology, Istituto Dermopatico dell’Immacolata – IRCCS, Roma, ItalyORCID Iconhttps://orcid.org/0000-0002-8839-5961View further author information
ORCID Icon,
Federico Pirrob Department of Dermatology, Università Cattolica Del Sacro Cuore, Rome, Italy;c Department of Dermatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ItalyORCID Iconhttps://orcid.org/0000-0001-6629-9613View further author information
ORCID Icon,
Gianluca Pagnanellik Department of Dermatology, Istituto Dermopatico dell’Immacolata – IRCCS, Roma, ItalyORCID Iconhttps://orcid.org/0000-0003-0961-6779View further author information
ORCID Icon,
Vincenzo Panasitil Plastic and Reconstructive Surgery Unit, Campus Bio-Medico University, Rome, ItalyView further author information
,
Alessia Provinik Department of Dermatology, Istituto Dermopatico dell’Immacolata – IRCCS, Roma, ItalyORCID Iconhttps://orcid.org/0000-0003-4127-9581View further author information
ORCID Icon,
Antonio Richettaf Unit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, ItalyORCID Iconhttps://orcid.org/0000-0002-7170-3972View further author information
ORCID Icon,
Lidia Sacchellim Department of Experimental, Diagnostic and Specialty Medicine, Dermatology Unit, University of Bologna, Bologna, Italy;n Dermatology, IRCCS Policlinico Di Sant’Orsola, University of Bologna, Bologna, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4388-4523View further author information
ORCID Icon,
Luca Bianchia Department of Dermatology, University of Rome Tor Vergata, Rome, ItalyORCID Iconhttps://orcid.org/0000-0001-8697-6896View further author information
ORCID Icon &
Ketty Perisb Department of Dermatology, Università Cattolica Del Sacro Cuore, Rome, Italy;c Department of Dermatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ItalyORCID Iconhttps://orcid.org/0000-0002-5237-0463View further author information
ORCID Icon show all
Pages 1291-1298 | Received 14 Apr 2021, Accepted 23 Jun 2021, Published online: 18 Jul 2021

References

  • Nestle FO, Kaplan DH, Barker J. Psoriais. N Engl J Med. 2009;361(5):496–509.
  • Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and metaanalysis of observational studies. J Am Heart Assoc. 2013;2(2):e000062.
  • Mrowietz U, de Jong EM, Kragballe K, et al. A consensus report on appropriate treatment optimization andtransitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol. 2014;28(4):438–453.
  • Ruiz-Villaverde R, Galán-Gutierrez M. Biosimilars in psoriasis: what should your positioning be? Expert Opin Biol Ther. 2020;27:1–6.
  • De Simone C, Caldarola G, Maiorino A, et al. Clinical predictors of nonresponse to anti-TNF-α agents in psoriatic patients: a retrospective study. Dermatol Ther. 2016 Sep;29(5):372–376.
  • Di Lernia V, Ricci C, Lallas A, et al. Clinical predictors of non-response to any tumor necrosis factor (TNF) blockers: a retrospective study. J DermatolTreat. 2014 Feb;25(1):73–74.
  • García-Doval I, Pérez-Zafrilla B, Ferrandiz C, et al., BIOBADADERM Study Group. Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort. J DermatolTreat. 2016;27(3):203–209.
  • van Winden MEC, van der Schoot LS, Van De L’isle Arias M, et al. Effectiveness and safety of systemic therapy for psoriasis in older adults: a systematic review. JAMA Dermatol. 2020;156(11):1229–1239.
  • Papp KA, Armstrong AW, Reich K, et al. Adalimumab efficacy in patients with psoriasis who received or did not respond to prior systemic therapy: a pooled post hoc analysis of results from three doulbe-blind, placebo-controlled clinical trials. Am J Clin Dermatol. 2016;17(1):79–86.
  • Strober BE, Poulin Y, Kerdel FA, et al. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am Acad Dermatol. 2011 Apr;64(4):671–681.
  • Lanna C, Zangrilli A, Bavetta M, et al. Efficacy and safety of adalimumab in difficult-to-treat psoriasis. Dermatol Ther. 2020;33(3):e13374.
  • Lanna C, Galluzzi C, Zangrilli A, et al. Psoriasis in difficult to treat areas: treatment role in improving health-related quality of life and perception of the disease stigma. J Dermatol Treat. 2020;1–4.
  • Warren RB, Marsden A, Tomenson B, et al. PSORT Consortium and on behalf of the BADBIR Study Group. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol. 2019 May;180(5):1069–1076.
  • Mourad A, Straube S, Armijo‐Olivo S, et al. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta‐analysis. Br J Dermatol. 2019;181(3):450–458.
  • van der Schoot LS, Van Der Reek JMPA, Groenewoud JMM, et al. Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry. J Eur Acad Dermatol Venereol. 2019;33(10):1913–1920.
  • Lie MRKL, Paulides E, van der Woude CJ. Patients sex does not affect endoscopic outcome of biological in inflammatory bowel disease but it is associated with adverse events. Int J Colorect Dis. 2020;35(8):1489–1500.
  • Bardazzi F, Bigi L, Campanati A, et al. Outcome following a short period of adalimumab dose escalation as rescue therapy in psoriatic patients. Eur J Dermatol. 2020;30(2):159–164.
  • Hojgaard P, Glintborg B, Kristenses LE, et al. The influece of obesity on response to tumor necrosis factor-a ihnhibitos in psoriatic arthritis: results from the DANBIO and ICEBO registries. Rheumatol. 2016;55(12):2191–2199.
  • Chiricozzi A, Zangrilli A, Bavetta M, et al. Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study. J Eur Acad Dermatol. 2017;31(2):304–311.
  • Rønholt K, L. I. Old and New Biological Therapies for Psoriasis. Int J Mol Sci. 2017;18(11):2297.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.